An osmotic diuretic is a type of diuretic that inhibits reabsorption of water and sodium (Na). They are pharmacologically inert substances that are given intravenously. They increase the osmolarity of blood and renal filtrate.
Osmotic diuretics works by expanding extracellular fluid and plasma volume, therefore increasing blood flow to the kidney. This washes out the cortical medullary gradient in the kidney. This stops the loop of Henle from concentrating urine, which usually uses the high osmotic and solute gradient to transport solutes and water.
Mechanism of actionEdit
Osmotic diuretics have their major effect in the proximal convoluted tubule and the descending limb of Henle's loop. These sites are freely permeable to water. Through osmotic effects, they also oppose the action of ADH in the collecting tubule. The presence of a nonreabsorbable solute such as mannitol prevents the normal absorption of water by interposing a countervailing osmotic force. As a result, urine volume increases.
The increase in urine flow rate decreases the contact time between fluid and the tubular epithelium, thus reducing sodium as well as water reabsorption. The resulting natriuresis is of lesser magnitude than the water diuresis, leading eventually to excessive water loss and hypernatremia.
Any osmotically active agent that is filtered by the glomerulus but not reabsorbed causes water to be retained in these segments and promotes a water diuresis. Such agents can be used to reduce intracranial pressure and to promote prompt removal of renal toxins. The prototypical osmotic diuretic is mannitol.
- "osmotic diuretic" at Dorland's Medical Dictionary
- "Mannitol". Retrieved 2008-12-20.
- Trevor, Anthony J.; Katzung, Bertram G. (2003). Pharmacology. New York: Lange Medical Books/McGraw-Hill, Medical Publishing Division. p. 46. ISBN 0-07-139930-5.
- Sakowitz OW, Stover JF, Sarrafzadeh AS, Unterberg AW, Kiening KL (February 2007). "Effects of mannitol bolus administration on intracranial pressure, cerebral extracellular metabolites, and tissue oxygenation in severely head-injured patients". J Trauma. 62 (2): 292–8. doi:10.1097/01.ta.0000203560.03937.2d. PMID 17297315.
- Brunton, Laurence (2011). Goodman & Gilman's: The Pharmacological Basis of Therapeutics (12th ed.). The McGraw-Hill Companies, Inc. pp. Chapter 25.
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|